Precision Medicine in Oncology

The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.

Latest News

New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
New KRYSTAL-1 Data Show 90% Intracranial Disease Control Rate in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases

August 16th 2023

ASCO 2023 logo
ASCO 2023: Solid Tumors

July 31st 2023

Cathy Eng, MD
FDA Sets Priority Review for Fruquintinib as ASCO Data Confirm Safety Results

June 20th 2023

CHEA LOGO
Conversations on Equity in Cancer Care: Meet the Leaders of NCCN’s DEI Directors Forum

April 17th 2023

David Jackman, MD
David Jackman, MD, on Clinical Pathway Buy-in, Process for Updates

February 23rd 2023

More News

DNA
November 29th 2021

Exploring the Use of Liquid Biopsy–Based Biosensors for MRD Assessment in NSCLC

Jaime Rosenberg
In a recent study, researchers detailed the use of various biosensors for minimal residual disease (MRD) detection in non–small cell lung cancer (NSCLC).
researchers in lab
November 27th 2021

Review Finds Room for Improvement in MRD Detection Via Liquid Biopsy for Solid Tumor Cancers

Rose McNulty
A recent review outlined advances and challenges in utilizing liquid biopsy to detect measures such as circulating tumor DNA in patients with solid tumors.
Doctors writing recommendations
November 24th 2021

Panel Offers Consensus Recommendations for MRD Assessment in CLL

Jaime Rosenberg
The recommendations come at a time when treatments for chronic lymphocytic leukemia (CLL), such as venetoclax, are making deep remissions and undetectable minimal residual disease (MRD) after a fixed duration of treatment feasible goals.
Palmetto GBA’s MolDX Announces Coverage of MRD Testing
November 20th 2021

Palmetto GBA’s MolDX Announces Coverage of MRD Testing

Matthew Gavidia Mary Caffrey
The decision will provide Medicare coverage tests for minimal residual disease (MRD) starting December 26, 2021.
Blood in tubes for testing
November 19th 2021

Can Conditionally Reprogramming Cells Expand the Scope of Precision Oncology?

Jaime Rosenberg
The approach works by transforming the condition of normal and tumor cells into a highly proliferative “reprogrammed stem-like” condition that still has the original karyotypes.
looking at graph
November 13th 2021

Case Study Indicates Drug Sensitivity Testing-Guided Treatment May Improve PFS in SRMS

Jaime Rosenberg
The drug sensitivity test-guided treatment was associated with significant improvements in the patient’s condition after 8 weeks.
diversity image
November 11th 2021

New Research Underscores Need for More Diversity in Precision Oncology Studies

Jaime Rosenberg
Across all studies included, observed-to-expected ratios showed that White and Asian patients were overrepresented while Black patients, Hispanic patients, and American Indian/Alaskan Native patients were underrepresented.
DNA
November 4th 2021

Tumor In Situ Fluid DNA Can Reveal Recurrence Risk in Glioma

Jared Kaltwasser
A study suggests tumor in situ fluid is a better choice when trying to extract tumor DNA in patients with glioma who underwent surgery.
lung graphic
November 2nd 2021

Study: Host Immune Classifier Test Predicts ICI Response in Advanced NSCLC

Jared Kaltwasser
Patients treated with immune checkpoint inhibitors had significantly different survival rates based on the test, regardless of PD ligand 1 classification.
Researchers Hope Single-Cell Tumor Immune Atlas Can Improve Predictions in Precision Oncology
October 26th 2021

Researchers Hope Single-Cell Tumor Immune Atlas Can Improve Predictions in Precision Oncology

Rose McNulty
A pan-cancer reference atlas provides a framework for an immune-based patient stratification that study authors expect to be predictive for patient prognosis and immunotherapy response at an elevated level after further studies.
Single-Cell RNA Sequencing May Lend Insights Into Lung Adenocarcinoma Prognosis
October 25th 2021

Single-Cell RNA Sequencing May Lend Insights Into Lung Adenocarcinoma Prognosis

Jared Kaltwasser
The report suggests factors besides molecular profiling can be helpful in patient stratification.
health graphic
October 19th 2021

Review: Era of Precision Medicine Dawning in Prostate Cancer

Jared Kaltwasser
An analysis of the latest research finds a robust approach to understanding particular prostate cancers remains necessary to finding optimal treatment.
Building a Patient-Centered Cancer Center From the Ground Up
October 13th 2021

Building a Patient-Centered Cancer Center From the Ground Up

Mary Caffrey
Researcher examining tissue samples
October 12th 2021

More Data Needed on Tissue-Agnostic Therapy Use in Breast Cancer

Emily Brill
This new study concluded that the breast cancer space needs more data to evaluate if there is a place for tissue-agnostic treatments for these patients.
Study Probes Role of Epigenetics in Precision Medicine for Lung Cancer
October 11th 2021

Study Probes Role of Epigenetics in Precision Medicine for Lung Cancer

Jared Kaltwasser
New modeling could help explain why some patients develop resistance to tyrosine kinase inhibitors.
The Promise of Liquid Biopsies for Cancer Diagnosis
October 11th 2021

The Promise of Liquid Biopsies for Cancer Diagnosis

Liz Kwo, MD, MBA, MPH Jenna Aronson
Site Logo
October 7th 2021

Providing Patients With Cancer Access to Affordable Housing During Treatment

Sushmita Gordhandas, MD Sarah Lee, MD, MBA Emeline M. Aviki, MD, MBA
Patients traveling for cancer treatment often incur financial burdens. The members of the Alliance of Dedicated Cancer Centers should play a role in mitigating housing-associated costs for patients during cancer treatment.
Abstracts at ASCO Quality Show Uptake of Rapid NGS, Biomarker Testing Across OneOncology
October 4th 2021

Abstracts at ASCO Quality Show Uptake of Rapid NGS, Biomarker Testing Across OneOncology

AJMC Staff
Using AI to Predict Outcomes in High-grade Extrauterine Serous Carcinoma
October 1st 2021

Using AI to Predict Outcomes in High-grade Extrauterine Serous Carcinoma

Allison Inserro
Artificial intelligence (AI) was used to predict response of high-grade extrauterine serous carcinoma (HGSC) to adjuvant platinum chemotherapy.
Image of acute lymphoblastic leukemia
September 23rd 2021

MRD Monitoring Useful Across Risk Groups in ALL

Jaime Rosenberg
In a recent paper, researchers outlined the utility of minimal residual disease (MRD) among patient with acute lymphoblastic leukemia (ALL) and how its monitoring at specific timepoints has proven useful for stratifying patients and helping to ensure appropriate treatment decisionsMRD
Graphic of GI system
September 19th 2021

Researchers Outline Ongoing Potential of ctDNA Analysis in GEA

Jaime Rosenberg
Unlike the success seen in other cancer types, biomarker-driven treatment advances in gastroesophageal adenocarcinoma (GEA) have been hindered by its genomic heterogeneity. A significant proportion of patients also develop resistant subclones through selective pressure, resulting in disease progression.
Phase 3 Data Solidify Cemiplimab’s Role in Second-Line Treatment of Cervical Cancer
September 18th 2021

Phase 3 Data Solidify Cemiplimab’s Role in Second-Line Treatment of Cervical Cancer

Mary Caffrey
In May, results showed that cemiplimab (Libtayo, Regeneron/Sanofi) produced significant benefits: a 31% reduction in the risk of death and a 25% reduction in the risk of disease progression.
Mobocertinib Approved in EGFR Exon 20 Insertion+ NSCLC
September 15th 2021

Mobocertinib Approved in EGFR Exon 20 Insertion+ NSCLC

Mary Caffrey
Patients with EGFR Exon20 insertion+ non–small cell lung cancer (NSCLC) make up approximately 1% to 2% of patients with NSCLC and have lacked treatment options.
Blood samples for testing
September 11th 2021

MRD May Be Useful for Guiding Treatment Decisions in Multiple Myeloma

Jaime Rosenberg
According to researchers, new findings may have important implications for expanding the use of measurable residual disease (MRD) in multiple myeloma.
German Study Shows Savings Using ClonoSEQ to Guide Multiple Myeloma Treatment
September 10th 2021

German Study Shows Savings Using ClonoSEQ to Guide Multiple Myeloma Treatment

Mary Caffrey
Study authors found that knowing a patient’s minimal residual disease status can help pinpoint the right multiple myeloma therapy to improve overall and progression-free survival.
A Review of Methods Being Investigated to Monitor MRD in MM
September 4th 2021

A Review of Methods Being Investigated to Monitor MRD in MM

AJMC Staff
A review looks at techniques to monitor minimal residual disease (MRD) in patients with multiple myeloma (MM).
Describing Sensitivity of ddPCR in Philadelphia-Positive ALL
September 2nd 2021

Describing Sensitivity of ddPCR in Philadelphia-Positive ALL

Jaime Rosenberg
The study, using a BCR/ABL1 assay, found that the novel method is able to detect minimal residual disease (MRD) in a larger range of patients compared with quantitative real‐time polymerase chain reaction, the method currently used to detect MRD.
artist rendering of Magnifying DNA
August 25th 2021

Study Finds Contrasting Genomic Profiles Among Tissue Samples, Liquid Biopsies of Prostate Cancer

Jaime Rosenberg
The genomic alterations in prostate cancer were detected from tissue biopsies of primary tumors and metastatic sites as well as from liquid biopsies of circulating tumor DNA, the latter of which has emerged as an increasingly popular method for genomic analyses across various types of cancer.
ctDNA Successfully Detects Mutations With Treatment Implications in mCRC
August 23rd 2021

ctDNA Successfully Detects Mutations With Treatment Implications in mCRC

Laura Joszt, MA
Circulating tumor DNA (ctDNA) is a noninvasive way to identify mutations that may impact treatment decisions, according to a study of patients with metastatic colorectal cancer (mCRC).
Oncology Value Coalition
August 16th 2021

Genomic Testing Creates Opportunities for Collaboration Between Academic Centers, Private Sector

Mary Caffrey
<12345678
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo